Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

Clinical Breast Cancer

Volumn 10, Issue 2, 2010, Pages 160-163

  Twelves, Chris ^a   Cortes, Javier ^b   Vahdat, Linda ^c   Wanders, Jantien ^d   Akerele, Corina ^e   Kaufman, Peter ^f  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d EISAI CO LTD   (Japan)

^e EISAI INC   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Capecitabine; EMBRACE; Microtubule dynamics inhibitor; Study design; Treatment of physician's choice

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; CAPECITABINE; ERIBULIN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SHORT SURVEY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77950475001     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.023     Document Type: Short Survey

References (14)

1. Bai RL, Paull KD, Herald CL, et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991; 266:15882-15889
2. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992; 55:31-51. (Pubitemid 23018631)
3. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61:1013-1021 (Pubitemid 32174419)
4. Yu MJ, Kishi Y, Littlefield BA. Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents from Natural Products. Boca Raton, FL: Taylor & Francis Group (CRC Press), 2005:241-265
5. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4:1086-1095 (Pubitemid 41079102)
6. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64:5760-5766 (Pubitemid 39095575)
7. Okouneva T, Azarenko O, Wilson L, et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7:2003-2011
8. Kuznetsov G, TenDyke K, Yu MJ, et al. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res 2007; 48275.
9. Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors. Clin Cancer Res 2009; 15:4207-4212
10. Tan AR, Rubin EH, Walton DC, et al. A phase I dose-finding study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15:4213-4218
11. Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial. J Clin Oncol 2005; 23(16 suppl):200s (abstract 3036).
12. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27:2954-2961
13. Vahdat L, Twelves C, Allison MA, et al. Phase II study of eribulin mesylate (E7389) in patients (PTS) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 2008; 26(suppl):62s (abstract 1084).
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216